ETBX-021
AXP000155.1 · Cancer vaccine
- Platform
- adenovirus (Ad5 [E1-, E2b-])
- Targets
- ERBB2
- Originator
- Etubics
- Sponsor
- ImmunityBio
Names
| Name | Type | Source |
|---|---|---|
| ETBX-021 | preferred name, code | curator, ncit |
| Ad5 [E1-, E2b-]-HER2/neu Vaccine ambiguous | synonym | ncit |
| Adenovirus Type 5 E1/E2b-deleted HER2/neu Vaccine ETBX-021 ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 [E1-, E2b-]
- Replication
- non replicating
- Modifications
- E1 and E2b regions deleted (replication-defective, reduced late gene expression)
- Transgenes
- HER2/neu
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C150517
- FDA UNII
- S4MK9TOL0D
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03563157 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Terminated | Phase 1/2 | 2018-09-28 | 2019-04-21 | 2 | Colorectal Cancer Metastatic; mCRC |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Withdrawn | Phase 2 | 2018-08 | 2019-12-30 | 0 | Metastatic Pancreatic Cancer |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | Withdrawn | Phase 1/2 | 2018-08 | 2019-01 | 0 | Colorectal Cancer |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Terminated | Phase 1/2 | 2018-07-17 | 2019-04-17 | 3 | Pancreatic Cancer |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | Withdrawn | Phase 1/2 | 2018-02 | 2019-01 | 0 | Non-small Cell Lung Cancer |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | Terminated | Phase 1/2 | 2018-01-09 | 2019-04-17 | 4 | Squamous Cell Carcinoma |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-02 | 0 | Ovarian Cancer |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-01 | 0 | Urothelial Carcinoma |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-01 | 0 | Head and Neck Squamous Cell Carcinoma |
| NCT02751528 | QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer | Terminated | Phase 1 | 2017-03-04 | 2018-08-16 | 3 | Cancer |
Recent changes
No changes recorded in its trials yet.
Notes
Ad5 [E1-, E2b-] vector of the Etubics (now ImmunityBio) AdenoVerse-style platform, given subcutaneously; the E2b deletion is intended to allow repeat dosing despite pre-existing Ad5 immunity. Studied alone and in the multi-antigen Tri-Ad5 / 'Triad' regimens, which are combinations and not programs of their own. NCIt preferred name: Ad5 [E1-, E2b-]-HER2/neu Vaccine.
How to cite
ETBX-021 (AXP000155.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000155.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.